Ondansetron-LENS, 2 mg/ml 4 ml

Ondansetron is a highly selective 5NT3 receptor antagonist. The mechanism of nausea and vomiting suppression is not exactly known. Radiation therapy and cytostatic drugs may release serotonin (5NT) in the small intestine, causing the gag reflex through activation of 5NT3 receptors and excitation of vagus nerve afferent fiber endings.

Indications

Active ingredient

How to take, the dosage

The choice of dosing regimen is determined by the emetogenicity of antitumor therapy.

For adults, the dose of Ondansetron-Lance is 8-32 mg/day.

In children over 2 years of age, the drug is administered by IV in a dose of 5 mg/m2 of body surface immediately before the start of chemotherapy followed by an oral dose of 4 mg 12 hours later

.

Special Instructions

In patients who received prior treatment with other selective 5HT3-receptor antagonists accompanied by hypersensitivity reactions, hypersensitivity reactions are also possible with Ondansetron-Lance.

Contraindications

– hypersensitivity to ondansetron or other components of the drug;

– concomitant use of ondansetron with apomorphine;

– pregnancy and breastfeeding;

– Children less than 6 months old with the indication “Prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy”;

– Children less than 1 month old with the indication “Prevention and treatment of postoperative nausea and vomiting in children”;

– Congenital QT interval prolongation syndrome.

Caution should be used in patients with hypersensitivity reactions to other 5NT3 receptor antagonists; in patients with cardiac rhythm and conduction disorders; in patients receiving antiarrhythmic agents and beta-adrenoblockers; in patients with significant electrolyte imbalances. Caution should be used with ondansetron in patients with prolongation or risk of QTc prolongation, including patients with electrolyte imbalance, congestive heart failure, bradyarrhythmias, or in patients taking other medications that may cause QT interval prolongation or electrolyte imbalance or decreased heart rate.

Side effects

CNS disorders: headache, dizziness, spontaneous motor disorders, seizures.

Cardiovascular system: chest pain (in some cases with ST-segment depression), arrhythmias, arterial hypotension, bradycardia.

Digestive system disorders: hiccups, dry mouth, diarrhea, constipation, transient asymptomatic increase in serum transaminase activity.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

Local reactions: pain, burning, redness at the injection site.

Others: rushes of blood to the face, fever, temporary visual acuity impairment, hypokalemia.

Similarities